Royalty Pharma Plc (RPRX) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$58.63

From 52W high−8.68%

Volume7.01M

Market cap$26.01B

P/E (TTM)24.2x

P/S (TTM)10.3x

Div yield1.58%

Key dataSep 18, 2026

Open

$58.63

From 52W high

−8.68%

Volume

7.01M

Market cap

$26.01B

ValuationView details →

P/E (Fwd)

12.5x

EV/EBITDA

21.6x

P/E (TTM)

24.2x

RSI (14)

41.1

MomentumView details →

1D Return

−0.88%

YTD Return

+50.62%

SummaryUpdated Jun 1, 2026

Royalty Pharma plc (NASDAQ:RPRX) is a leading buyer of biopharmaceutical royalties and funder of innovation in the healthcare industry. Founded in 1996 and based in New York, the company went public in June 2020. Royalty Pharma operates as a specialized investment firm that acquires royalty streams from successful pharmaceutical and biotechnology products, providing capital to innovators while generating returns for shareholders through predictable cash flows from marketed therapies and development-stage products.

Ask drillr about Royalty Pharma Plc →

ValuationView details →

P/E (Fwd)

12.5x

P/E (TTM)

24.2x

EV/EBITDA

21.6x

EV/Sales

14.6x

P/S (TTM)

10.3x

P/B (TTM)

3.8x

ProfitabilityView details →

Gross Margin

89.38%

Net Margin

32.15%

EBITDA Margin

67.66%

ROE (TTM)

11.93%

ROA (TTM)

4.11%

Asset Turnover

0.13x

GrowthView details →

Revenue YoY

+10.01%

EPS YoY

+3.27%

FCF YoY

+23.70%

Revenue CAGR 3Y

+2.06%

EPS CAGR 3Y

+187.74%

EBITDA YoY

−11.14%

MomentumView details →

1D Return

−0.88%

YTD Return

+50.62%

1Y Return

+60.60%

RSI (14)

41.1

vs 50D SMA

−1.85%

vs 200D SMA

+16.12%

Capital & dividendView details →

Debt/Equity

1.31x

Current Ratio

1.29x

Quick Ratio

1.29x

Div Yield

1.58%

Div Rate

$0.92

Div Growth 1Y

+4.76%

EarningsView details →

EPS (Actual)

$1.32

EPS Surprise

3.94%

Beats (12Q)

8/12

Next Q EPS Est

$1.18

Avg Surprise (4Q)

9.49%

Rev Surprise

1.85%

Financials snapshotView financials →

Revenue (TTM)

2.54B

Net Income (TTM)

815.30M

Op. CF (TTM)

2.98B

Next earningsNov 4, 2026 →

Latest newsMore news →

Royalty Pharma announced a $7.5 million gift to Blood Cancer United to expand its Therapy Acceleration Program, a venture philanthropy initiative funding blood cancer therapies.5d ago

Royalty Pharma agreed to provide $100 million in funding to Zealand Pharma in exchange for economics related to rusfertide (PTG-300), a potential first-in-class therapy for polycythemia vera.39d ago

Similar companies

InnoCare Pharma Limited09969.HK Insmed IncorporatedINSM Incyte CorporationINCY Biocytogen Pharmaceuticals (Beijing) Co., Ltd.02315.HK 特宝生物688278.SH BioNTech SEBNTX Find similar companies →

Latest newsMore news →

Royalty Pharma announced a $7.5 million gift to Blood Cancer United to expand its Therapy Acceleration Program, a venture philanthropy initiative funding blood cancer therapies.5d ago Royalty Pharma agreed to provide $100 million in funding to Zealand Pharma in exchange for economics related to rusfertide (PTG-300), a potential first-in-class therapy for polycythemia vera.39d ago